Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31364464 | 1.00 | KMT2A (0.56) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10927175 | 0.94 | KMT2A (0.51) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10926803 | 0.90 | ADRA1D (0.55) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10927835 | 0.88 | KMT2A (0.48) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL10927830 | 0.88 | KMT2A (0.48) | KMT2ACASP3GRM5NPSR1BRD4 | |
| SCHEMBL16862983 | 0.86 | KDM4E (0.66) | KMT2AGRM5NPSR1BRD4ADRA1D | |
| SCHEMBL21997738 | 0.85 | CASP3 (0.55) | KMT2ACASP3GRM5BRD4ADRA1D | |
| SCHEMBL10925461 | 0.84 | ADRA1D (0.58) | KMT2ACASP3NPSR1ADRA1DADRA1A | |
| SCHEMBL18954624 | 0.84 | ALDH1A1 (0.64) | BRD4PKMTSHRALDH1A1MAPT | |
| SCHEMBL2258501 | 0.83 | KMT2A (0.70) | KMT2ACASP3NPSR1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3539963-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Livo (Shanghai) Pharmaceutical Co., Ltd (CN) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018086593-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | 礼沃（上海）医药科技有限公司 | 2018-05-17 | — | — | WO | disclosed |
| CN-101531631-B | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP | 2011-09-28 | — | — | CN | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| EP-0758341-B1 | FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1384725-A2 | Factor Xa inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| US-5849510-A | Factor Xa inhibitors | SELECTIDE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0545376-B1 | Guanidino thiazoles and their use as H2-receptor antagonist | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-09-09 | — | — | EP | disclosed |
| EP-0758341-A1 | FACTOR Xa INHIBITORS | SELECTIDE CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5532258-A | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| WO-1995029189-A1 | FACTOR Xa INHIBITORS | SELECTIDE CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0545376-A1 | Guanidino thiazoles and their use as H2-receptor antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | KMT2A 4674/4885CASP3 1614/4885GRM5 985/4885 |
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | TLR7, TLR9, TLR4 | KMT2A 2046/4885CASP3 2023/4885GRM5 1465/4885 |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | TLR7, TLR9, NOD1 | KMT2A 2141/4885CASP3 2917/4885GRM5 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.